Colon Cancer Liver Metastasis
Conditions
Brief summary
This is a multicentre, open labeled, single arm study to determine effectiveness and safety of chemoembolization with Irinotecan-Eluting Bead(DEBIRI) in the treatment of unresectable liver metastases in patients with colorectal cancer after chemotherapy failure.
Interventions
PROCEDURETACE
Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
DRUGIrinotecan
Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
DEVICEeluting-bead
The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients over 18 years of age, of any race or sex, who have histologic or radiologic proof of colorectal cancer to the liver, who are able to give informed consent, will be eligible. 2. Patients with primary colorectal lesions removed, and negative extrahepatic metastasis 3. Patients with at least one measurable liver metastases, with size \> 2cm or less than 5 liver metastases,with size smaller than 10cm. 4. Patients have received at least six cycle system chemotherapy based irinotecan or oxaliplatin and got a failure outcome; or patients who are intolerance of operation. 5. No intervention therapy was received for liver lesions during one year. 6. Life expectancy of \> 3 months 7. Child-pugh's grade A or B (no more than 7 score). 8. Eastern Cooperative Oncology Group (ECOG) Performance Status score of \< 2 9. Signed, written informed consent
Exclusion criteria
1. Patients with extrahepatic metastasis 2. Patients has received TACE,ablation and iodine seed implantation for liver lesions during one year. 3. With obvious arterio-venous fistula 4. Patients suffered with other cancer(Except for cured basal or squamous cell skin cancer or cervical carcinoma in situ) 5. Hematologic function: leukocytes \<3000cell/mm3, platelets\<50000/mm3, with no hypersplenism. 6. Adequate renal function (creatinine ≤ 2.0mg/dl) 7. Alanine transaminase(ALT) and/or glutamic oxalacetic transaminase(AST) \>5 times upper limit of normal(ULN) 8. International Normalized Ratio (INR) \>1.5, or being treated by anticoagulants, or being suffered hemorrhagic disease. 9. With serious heart, kidney, bone marrow, or lung, central nervous system diseases. 10. With recent infections and received antibiotics. 11. Other conditions place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Response of two months | Two months post first treatment | Response rate(RR) |
| Tumor Response of four months | four months post first treatment | Response rate(RR) |
| Tumor Response of six months | Six months post first treatment | Response rate(RR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | From date of first treatment until the date of death from any cause, whichever came first, assessed up to 24 months | overall survival(OS) |
| Quality of life | Six months post first treatment | Assesment Quality of life by EORTC QOL-C30 questionnaire |
| Time to intrahepatic progression | From date of first treatment until the date of intrahepatic progression, whichever came first, assessed up to 24 months | Time to intrahepatic progression(THP) |
| Time to extrahepatic progression | From date of first treatment until the date of extrahepatic progression, whichever came first, assessed up to 24 months | Time to extrahepatic progression(TEP) |
Countries
China
Contacts
Primary ContactZhi Guo, PhD
Backup ContactXueling Yang, PhD
Outcome results
None listed